We are broadly supportive of the three strategic priorities described previously and welcome the newly included elevated strategic priority on effective governance and financing, which also recognizes the important role of all stakeholders, including the private sector.

The WHA report continues to acknowledge the need for specific solutions to tackle the pipeline and access crises, including working with industry. It is critical the report recognizes the unsustainable economics of antibiotic research and development (R&D) as a core driver of the deteriorating clinical pipeline, which together with diverse barriers to access contributes to uneven availability of effective antibiotics.

We recommend the report acknowledges the need for well-studied and tested incentive solutions that support a healthy antibiotic R&D ecosystem, in support of the proposed strategic objectives. We also welcome the inclusion of the “Prevention” pillar and the role of vaccines. Ahead of the High-Level Meeting on AMR (HLM), we also call on Member States to consider ambitious objectives on AMR, including a mechanism for developing up-to-date evidence to inform possible targets and priority actions in AMR areas where evidence is lacking.